[Pharmacoeconomics aspects of long-acting beta-2 agonists in COPD patients].
Pharmacoeconomics is the scientific discipline that assess the overall value of pharmaceutical health care products, services, and programs. Several potential uses for pharmacoeconomic analysis are pharmaceutical reimbursement, price negotiations, formulary discussions, clinical practice guideline developments, and communications to prescribing physicians. Bronchodilatator medications, including SABA (slow acting beta-2 agonists) and LABA (long acting beta-2 agonists) are central to the symptomatic management of COPD. LABA in Evidence Based Medicine related treatment of COPD patients is presented in this article. In the second part issues regarding the limitations and interpretations of COPD clinical trials have been discussed. The important role of cost-effectiveness analyses in LABA reimbursement and drug pricing strategy in Poland have been stressed.
Jahnz-Rózyk
Karina
K
Wojskowy Instytut Medyczny w Warszawie: Zakład Immunologii i Alergologii Klinicznej. krozyk@poczta.onet.pl
Targowski
Tomasz
T
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000191:economics*; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D006801:Humans; D011044:Poland; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000191:economics
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists